Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study

Phase 4

Terminated

Conditions: Myelodysplastic Syndrome
Transfusional Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2011-03-31

Last Posted Date: 2017-03-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT01326845

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: INC280

First Posted Date: 2011-03-29

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 131

Registration Number: NCT01324479

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Karmanos Cancer Institute Wayne St Karmanos, Detroit, Michigan, United States
🇹🇭
Novartis Investigative Site, Songkhla, Hat Yai, Thailand

and more 3 locations

Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Phase 1

Completed

Conditions: Lung Neuroendocrine Neoplasm

Interventions: Drug: RAD001

First Posted Date: 2011-03-29

Last Posted Date: 2014-12-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT01324492

Locations: 🇨🇳
Novartis Investigative Site, Shenyang, Liaoning, China

ACZ885 in Type 1 Diabetes Mellitus

Phase 2

Withdrawn

Conditions: Diabetes Mellitus
Diabetes Type 1

Interventions: Drug: ACZ885
Drug: Placebo

First Posted Date: 2011-03-24

Last Posted Date: 2012-09-05

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01322321

Locations: 🇨🇦
LMC Endocrinology Centres (Barrie) Ltd, Barrie, Ontario, Canada
🇬🇧
Novartis Investigative Site, Liverpool, United Kingdom
🇨🇦
LMC Endocrinology Centres (Bayview) Ltd, Toronto, Ontario, Canada

and more 1 locations

Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients

Phase 2

Completed

Conditions: Detection Accuracy
Patient Compliance

Interventions: Drug: ECMPS-IEM

First Posted Date: 2011-03-22

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT01320358

Locations: 🇨🇭
Inselspital Bern / Nephrology, Bern, Switzerland
🇨🇭
Kantonspital Aarau AG / Nephrologie, Aarau, Switzerland
🇨🇭
University Hospital Basel, Basel, Switzerland

and more 2 locations

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting

Completed

Conditions: Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Retinal Vein Occlusion
Diabetic Macular Edema
Wet Age Related Macular Degeneration

Interventions: Other: Ranibizumab

First Posted Date: 2011-03-21

Last Posted Date: 2016-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30490

Registration Number: NCT01318941

Locations: 🇻🇪
Novartis Investigative Site, Torre Venezuela, Piso 1, Venezuela

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Phase 4

Completed

Conditions: Carcinoma, Large Cell
Neuroendocrine Tumors

Interventions: Drug: RAD001
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2011-03-17

Last Posted Date: 2016-03-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT01317615

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Phase 2

Completed

Conditions: Genital Neoplasms, Male
Neoplasms, Abdominal
Antineoplastic Agents
Prostatic Neoplasm
Urogenital Neoplasms
Prostatic Diseases
Imatinib
Genital Diseases, Male

Interventions: Drug: STI571 (Glivec®)

First Posted Date: 2011-03-16

Last Posted Date: 2017-06-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT01316458

Locations: 🇩🇪
Novartis Investigative Site, Wuppertal, Germany
🇩🇪
Novarts Investigative Site, Hamburg, Germany

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

Phase 4

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Standard MS DMT
Drug: Fingolimod

First Posted Date: 2011-03-16

Last Posted Date: 2015-06-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 61

Registration Number: NCT01317004

Locations: 🇮🇹
Novartis Investigative Site, Novara, Italy

A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema

Phase 4

Completed

Conditions: Visual Impairment
Macular Edema

Interventions: Drug: Ranibizumab

First Posted Date: 2011-03-15

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 394

Registration Number: NCT01315275

Locations: 🇫🇷
Novartis Investigative Site, Vannes, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy